The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation XXXX .

@entity1 @entity1187 @entity548 @entity27408 @entity49 @entity173 @entity1211 @entity6236
Fondaparinux (Arixtra), a synthetic pentasaccharide, is the first in a new class of antithrombotic agents that selectively inhibit coagulation @entity6236 . In vitro experiments demonstrated that it is a selective inhibitor of @entity6236 . In plasma, fondaparinux selectively binds to antithrombin, catalyzes @entity6236 inhibition, and thereby inhibits thrombin generation. Its antithrombotic efficacy has been demonstrated in various animal models mimicking @entity49 . In @entity1 , its pharmacokinetic profile is favorable, with a rapid onset of antithrombotic activity and an elimination half-life allowing a convenient once-daily dosing regimen. In several clinical trials, @entity27408 was more effective than the reference drug, enoxaparin, in preventing @entity1211 after @entity173 , major knee, and elective hip replacement surgeries. The overall reduction in the risk of @entity1211 ranged between 26.3 and 56.4%, depending on the trial. This superior efficacy was achieved without increasing the risk of clinically relevant @entity548 . Fondaparinux also showed promising results in the treatment of @entity1 with @entity1211 and @entity1187 . Thus, it is now established that selective @entity6236 inhibition is an efficient way to prevent @entity49 . The advent of fondaparinux offers an opportunity to improve substantially the management of @entity1211 .
